Using pyridostigmine to treat postoperative ileus after colorectal surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a double-blind, placebo-controlled, randomized trial assessing the safety and efficacy of pyridostigmine as a rescue therapy for postoperative ileus in patients who have undergone elective colorectal surgery. Eligible participants will be those who develop symptoms of ileus, such as bloating and absence of bowel movement, after their surgery. Patients will be randomly assigned to receive either pyridostigmine or a placebo, alongside standard care, and will be monitored for side effects using a specific scale. The study aims to determine if pyridostigmine can effectively alleviate postoperative ileus symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult (age 18 and over) patients with benign or malignant colonic or rectal disease who have undergone elective laparoscopic, robotic, or open colorectal resections with or without ostomy construction at our center, and subsequently developed POI, defined as symptoms of bloating with or without nausea and vomiting, with absence of passage of flatus or stool for at least 48 hours postoperatively and require return to NPO status after initial diet attempts with or without placement of an NGT.
2. Radiographic confirmation of POI diagnosis either via abdominal radiography (KUB), computed tomography abdomen/pelvis (CT A/P), or both
3. ECOG Performance status \< 4
4. Laboratory evidence of normal organ function, defined as:

   1. Hemoglobin ≥ 7.0 g/dL
   2. WBC ≤ 20,000/mcL and ≥ 4,000/mcL
   3. Platelet count ≥ 100,000/mcL or ≤ 100,000,000/mcL
   4. AST (SGOT) ≤ 2.5 times the institutional upper limit of normal
   5. ALT (SGPT) ≤ 2.5 times the institutional upper limit of normal
   6. Total bilirubin within the upper limit of institutional normal range
   7. Serum Creatinine within the upper limit of institutional normal range

Exclusion Criteria:

1. Radiographic evidence of bowel obstruction
2. Documented intraabdominal septic complications (IASC, such as abdominopelvic abscess, peritonitis, anastomotic leak) at any time prior to or after enrollment
3. Isolated small bowel or ostomy surgery without colon or rectal resection
4. ASA score 5
5. Pregnant or breastfeeding females as PYR is classified by the FDA as a pregnancy risk category C medication with the potential for teratogenic or abortifacient effects and demonstrated secretion into breastmilk with an unknown but potential risk for adverse effects in the nursing infants
6. Current use of any other investigational agents including: neostigmine or other acetylcholine esterase inhibitors, alvimopan, metoclopramide, erythromycin, methylnaltrexone, naloxegol, cisapride, and laxatives or cathartics (i.e. milk of magnesia, polyethylene glycol)
7. History of allergic reactions attributed to PYR or other acetylcholine esterase inhibitors
8. Patients with any of the following uncontrolled, concurrent illnesses: active or latent MG, bronco-constrictive disease (asthma/reactive airway disease), chronic obstructive lung disease (COPD), symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia including bradycardia, renal failure, hepatic failure, gastroparesis, short bowel syndrome (small bowel \< 200cm), preexisting short or large bowel dysmotility or pseudo-obstruction, chronic constipation/laxative use, peritoneal carcinomatosis, and psychiatric illness/social situations that would limit compliance with study requirements

Where it's running

• Cleveland Clinic Main Campus
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Stefan D Holubar — The Cleveland Clinic
• Study coordinator: Stefan D Holubar
• Email: holubas@ccf.org
• Phone: 2164447000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bowel Sounds and Day-to-Day Recovery After Colorectal Cancer Surgery

  This study will test whether monitoring bowel sounds before and after colorectal cancer surgery can predict how quickly patients recover bowel function and resume eating.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07705139

• Liposomal Bupivacaine TAP Block Plus Pain Control to Help Gut Recovery After Major Abdominal Surgery

  This trial tests whether adding liposomal bupivacaine TAP block to a sufentanil or oxycodone-based pain plan helps people recover gut function after major abdominal surgery.

  Recruiting Tianjin First Central Hospital · Tianjin, Tianjin Municipality · NCT07651722

• Restrictive versus liberal IV fluids during elective cesarean with spinal anesthesia

  This trial will test whether giving less versus more IV fluids during spinal anesthesia reduces nausea and speeds bowel recovery for women having an elective cesarean.

  Recruiting Nigde Omer Halisdemir University · Niğde, Merkez · NCT07440667

• Chewing gum to speed bowel recovery after open gastrointestinal surgery

  This trial will test whether chewing glucose-containing gum after open gastrointestinal surgery helps adults' intestines start working sooner.

  Recruiting Khyber Medical University Peshawar · Peshawar, KPK · NCT07425249

• Tegileridine for faster bowel recovery after abdominal surgery

  This trial tests if tegileridine, given after abdominal surgery, helps the gut start working sooner compared with morphine while both are used with a patient-controlled pump.

  Recruiting at 3 sites Phase 4 Xiangya Hospital of Central South University · Guangzhou, Guangdong and 2 other locations · NCT07412223

• Thread-embedding acupuncture to speed bowel recovery after colorectal cancer surgery.

  This trial will test whether adding thread embedding acupuncture (with electroacupuncture) helps adults recover bowel function faster after elective laparoscopic colorectal cancer surgery.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07071987

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.